D-GsMTx4 TFA
目录号 : KM31832A 纯度 : 99%

D-GsMTx4 TFA 是一种蜘蛛肽和 GsMTx4 的 D 对映体。D-GsMTx4 TFA 抑制机械敏感离子通道 Piezo2。D-GsMTx4 TFA 抑制 [Ca2+]i 升高。D-GsMTx4 TFA 抑制 mTOR 和 PI3K-Akt 信号通路。D-GsMTx4 TFA 抑制机械性异常性疼痛和热痛觉过敏。D-GsMTx4 TFA 可用于机械应力、慢性疼痛和特发性肺纤维化研究。

规格 价格 是否有货 数量
1mg
In-stock

Other Forms of Rapamycin:

KKL Med 的所有产品和服务仅用于科学研究,不能被用于人体,兽医,我们也不向个人提供产品和服务。
生物活性

D-GsMTx4 TFA is a spider peptide and the D enantiomer of GsMTx4 D-GsMTx4 TFA inhibits the mechanosensitive ion channel Piezo2. D-GsMTx4 TFA inhibits [Ca2+]i elevation. D-GsMTx4 TFA inhibits mTOR and PI3K-Akt signaling pathways. D-GsMTx4 TFA inhibits mechanical allodynia and thermal hyperalgesia. D-GsMTx4 TFA can be used in researches of mechanical stress, chronic pain and idiopathic pulmonary fibrosis.

体外研究

D-GsMTx4 TFA (5-10 µM) dose dependently and reversibly inhibited Piezo2 mediated mechanosensitive inward current in QGP-1 cells and HEK-293 cells transfected with human Piezo2.
D-GsMTx4 TFA can reduce the phosphorylation levels of proteins in the mTOR and PI3K Akt signaling pathways in primary human lung fibroblasts (HLF).
D-GsMTx4 TFA (5 µM) can inhibit the increase of [Ca2+] i induced by mechanical stimulation in DRG neurons cultured from CYP induced cystitis rats .

体内研究

D-GsMTx4 TFA (10 μg/10 μL; subcutaneous injection; IL-1 β injection at 1 hour significantly inhibited mechanical allodynia and thermal hyperalgesia in a rat model of oral and facial inflammatory pain induced by IL-1 β.
D-GsMTx4 TFA (5-10 μg/50 μL; subcutaneous or intrathecal injection) can significantly alleviate mechanical allodynia in a rat model of oral and facial neuropathic pain induced by inferior alveolar nerve injury.

 

Animal Model: Male Sprague Dawley rats with IL-1β-induced inflammatory pain
Dosage: 10 μg/10 μL (normal saline)
Administration: Subcutaneous injection, 1 h after IL-1β injection
Result: Significantly blocked IL-1β-induced mechanical allodynia and thermal hyperalgesia, with antiallodynic effects lasting 3-7 h.
 
分子式
C185H273N49O45S6.XC2Hf3O2
分子量
4095.84 (free base)
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式

2-8°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据
In Vitro:

DMSO : 100 mg/mL (Need ultrasonic)

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO → 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (Infinity mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (Infinity mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD ⽣理盐⽔⽔溶液中,混合均匀。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
动物实验计算换算器
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。

配置后的溶液总体积:

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。